Guardant health and quest diagnostics announce strategic collaboration to broaden access to guardant's shield™ blood-based screening test in the united states

Palo alto, calif. & secaucus, n.j.--(business wire)---- $gh--guardant health, inc. (nasdaq: gh), a leading precision oncology company, and quest diagnostics (nyse: dgx), a leader in diagnostic information services, today announced a broad strategic collaboration to make guardant's shield™ blood-based screening test available to physicians and patients served by quest in the united states. shield is the first and only blood test to receive full fda approval as a primary screening option for colorectal c.
DGX Ratings Summary
DGX Quant Ranking